Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice

Annals of Oncology

Volumn 11, Issue 11, 2000, Pages 1437-1443

  Taal, B G ^a   Hoefnagel, C ^a   Boot, H ^a   Valdes Olmos R ^a   Rutgers, M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Biodistribution; Carcinoid tumours; MIBG; Tumour targeting

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; (3 IODOBENZYL)GUANIDINE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; IODINE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PALLIATIVE THERAPY; CARCINOID; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; MALE; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOACTIVITY; XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; COMPARATIVE STUDY; DRUG SCREENING; EVALUATION; MIDDLE AGED; PATHOLOGY; SCINTISCANNING; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

3-IODOBENZYLGUANIDINE; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOID TUMOR; DRUG EVALUATION; FEMALE; HUMANS; IODINE ISOTOPES; IODINE RADIOISOTOPES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0033622498     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026592025862     Document Type: Article

References (21)

1. Neuroendocrine gastrointestinal tumours
2. Meta-iodobenzylguanidine and somatostatin in oncology: Role in the management of neural crest tumours
3. 111In-Pentetreotide in carcinoid tumours
4. Palliative effect of meta-iodobenzylguanidine in metastatic carcinoid tumours
5. 131I-labeled MIBG and the combination
6. The human carcinoid cell line, BON. A model system for the study of carcinoid tumours
7. 131I]MIBG in xenografted BALB/c nu/nu mice
8. 131I-MIBG
9. Diagnosis and treatment of a carcinoid tumour using iodine-131 metaiodobenzylguanidine
10. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: A prospective study in 39 patients
11. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome
12. Bioavailability and toxicity after oral administration of meta-iodobenzylguanidine (MIBG)
13. Radio-iodinated meta-iodobenzylguanidine: A review of its biodistribution and pharmacokinetics, drug interaction and dosimetry
14. Successful and unsuccessful approaches to imaging carcinoids: Comparison of a radiolabeled tryptophan hydroxylase inhibitor with a tracer of biogenic amine uptake and storage, and a somatostatin analogue
15. Uptake of the neuron-blocking agent meta-iodobenzylguanidine and serotonin by human platelets and neuro-adrenergic tumour cells
16. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRI)
17. Molecular physiology of norepinephrine and serotonin transporters
18. Positron emission tomography with 5-hydroxytryptophan in neuroendocrine tumours
19. Expression of vesicular monoamine transporters in endocrine hyperplasia and endocrine tumors of the oxyntic stomach
20. Intracellular inhibition of mono (APD-ribosylation) by meta-iodobenzyl-guanidine: Specificity, intracellular concentration and effects on glucocorticoid-mediated cell lysis
21. Potentiation of anticancer drugs at low intratumoural pH induced by the mitochondrial inhibitor meta-iodobenzylguanidine (MIBG) and it analogue benzylguanidine (BG)